Read more
1:31 PM · 13 May 2020

Gilead Sciences signed a deal for remdesivir.

Gilead Sciences (GILD.US)   announced that it had struck a licensing agreement to produce the antiviral drug remdesivir in 127 countries, not including the US. The company’s will work with five generic drugmakers to produce the potential drug for coronavirus. Among them is Mylan (MYL.US), which is the world's largest producer of generic drugs.


Gilead Sciences (GILD.US)  shares rose 1.96% in pre-market trading. If positive mood persists, then resistance at $86.16 per share may be tested. Source: xStation5

1 May 2026, 3:40 PM

US Open: Hope for De-escalation Bolsters Wall Street Bulls

30 April 2026, 9:44 PM

Apple earnings beat Wall Street estimates 🚨 iPhone sales below expectations

30 April 2026, 3:41 PM

🗽S&P 500 companies with the record net margin since 2009 - FactSet data

30 April 2026, 2:04 PM

Market Wrap: UK100 skyrockets after BoE 🇬🇧 🚀 Euphoric gain as ECB Lagarde speaks 🇪🇺 📈

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits